Mouse Molecular Technologies

Mouse Pipelines

The team provides high-throughput genotyping and characterisation of mutant mouse strains created either by targeted embryonic stem cells or CRISPR/Cas9 gene editing

The Mouse Molecular Technologies team provide high-throughput genotyping and characterisation of mutant mouse strains created either by targeted embryonic stem cells (ESC) or CRISPR/Cas9 gene editing in single-cell zygotes. Each strain contains an alteration in a single gene, the structure of which must be verified prior to breeding and phenotyping.

The mice are genotyped by either end-point PCR or real-time qPCR to determine how many copies of the mutant gene each individual posesses. Mice can then be bred to sufficient numbers and in the correct way for phenotyping

The Mouse Molecular Technologies team works with the Mouse Genome Engineering, Mouse Transgenic Technologies and Mouse Phenotyping teams under the umbrella of Mouse Pipelines.

The Mouse Pipelines team is responsible for delivering the large-scale projects under its responsibility, including the Sanger Mouse Genetics Project, the National Institutes of Health KOMP2 production and phenotyping, the EUCOMMTools, and the Infrafrontier projects.

In addition the team is closely involved in three major Strategic Award projects funded by the Wellcome Trust:

  • Deciphering the Mechanisms of Developmental Disorders (DMDD)
  • Origins of Bone and Cartilage Disease (OBCD)
  • Immune function and pathology dissected by high-throughput analysis of mice with targeted gene disruptions – an investigation by the Infection and Immunity Immunophenotyping (3i) consortium.

We serve the scientific community with genetically altered strains of mice by supplying public repositories and researchers directly. Availability of these mouse strains is complemented by the standardised phenotypic characterisation performed by Mouse Pipelines, that is freely available to the scientific community. Accordingly, the research community continues to produce a growing scientific output using the resources distributed from the Mouse Pipelines at the Institute. To support this important part of our mission, we have an office to carry out cost-recovery.

The team researches and develops mouse resource production methods. For example we are implementing the use of the CRISPR mouse mutagenesis technology directly in mouse embryos, which will lead to great savings and acceleration of projects in their early phase by removing the need to use embryonic stem cells. We work flexibly so that we can rapidly shift our resources to advance all large-scale projects as needed while also supporting the needs of individual Faculty members.

We work closely with the Mouse Informatics and Research Support Facility teams to develop the Mouse Database. This work is essential for the welfare of our mice, to maintain optimal operational workflows, and to achieve our scientific goals, as well as for streamlining publication of our scientific results through the International Mouse Phenotyping Consortium (IMPC) web portal.

Our people

Previous team members

Photo of Dr Ed Ryder

Dr Ed Ryder

Senior Scientific Manager, Mouse Molecular Technologies


We work with the following groups



Loading publications...